

Active Clinical Trials

- **AMPLATZER™ PFO Occluder Post Approval Study**
 Abbott
 Objective: This study is intended to demonstrate the safety and effectiveness of the AMPLATZER™ PFO Occluder in patients with a **patent foramen ovale who have had a cryptogenic stroke.**
[Dr. Adam Saltzman](#)
[Dr. Benjamin Zorach](#)
No longer enrolling
 NCT # 03309332
- **Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP TOO)**
 Boston Scientific
 Objective: The primary objective is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with **non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy** to reduce the risk of stroke.
[Dr. Adam Saltzman](#)
[Dr. Ramin Davoudi](#)
[Dr. Nitesh Sood](#)
No longer enrolling
 NCT# 02928497
- **CHAMPION AF (CHAMPION)**
 Boston Scientific
 Objective: The primary objective of this study is to determine if left atrial appendage closure with the Watchman device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with **non-valvular atrial fibrillation.**
[Dr. Adam Saltzman](#)
[Dr. Ramin Davoudi](#)
[Dr. Nitesh Sood](#)
No longer enrolling
 NCT # 04394546
- **Post-Approval Study Protocol For Hybrid Convergent Of Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF (CONVERGE POST-APPROVAL STUDY (PAS))**
 AtriCure
 Objective: The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System to **treat symptomatic long-standing persistent atrial fibrillation (AF)** patients who are **refractory or intolerant to at least one Class I and/or III AAD.**
[Dr. Nitesh Sood](#)
[Dr. Ramin Davoudi](#)
[Dr. Arnold Giedrimas](#)

[Dr. Jacob Kriegel](#)

[Dr. Peter Lee](#)

Currently enrolling

NCT# 05393180

- **STOP AF PAS**

Medtronic

Objective: Demonstrate the superiority of cryoballoon ablation as compared to antiarrhythmic drug (AAD) therapy in terms of the rate of freedom from atrial fibrillation/atrial flutter in a **non-drug refractory paroxysmal atrial fibrillation population.**

[Dr. Nitesh Sood](#)

[Dr. Ramin Davoudi](#)

[Dr. Arnold Giedrimas](#)

Currently enrolling

NCT# 027532737

- **A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation/ AVANT GUARD**

Boston Scientific

Objective: The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with **persistent atrial fibrillation** as compared to subjects who received an initial treatment with antiarrhythmic drugs.

[Dr. Nitesh Sood](#)

[Dr. Arnold Giedrimas](#)

Currently enrolling

NCT# 06096337

- **VOLT AF-IDE**

Abbott Medical

Objective: The objective of the VOLT-AF study is to demonstrate that the Volt™ PFA System (Volt PFA System) is safe and effective for the treatment of **symptomatic, recurrent, drug refractory paroxysmal and persistent atrial fibrillation (AF).**

[Dr. Ramin Davoudi](#)

[Dr. Arnold Giedrimas](#)

No longer enrolling

NCT# 06223789

- **IMACOR One Touch Hemodynamics (OTH) Auto Segmentation Algorithm Performance Assessment Non-Significant Risk (NSR) Study**

IMACOR

Objective: Via transesophageal echocardiogram, provide direct visualization of cardiac filling and function to assess and guide interventions for **critically ill patients in high acuity settings.**

[Dr. Christopher Abadi](#)

Currently enrolling

NCT# 02048566

- **JET Enhanced Thrombectomy Intervention** (JETi Registry)
 Walk Vascular
 Objective: A prospective, multi-center observational registry with primary objectives to assess the **percent change in occlusion** from pre-JETi post-JETi **thrombectomy** and to assess outcomes of those affected by rethrombosis of the treated vessels throughout a 12 month follow up.
[Dr. Richard Pin](#) (also National Principal Investigator)
[Dr. Mark Perry](#)
[Dr. Christopher Tanga](#)
No longer enrolling
 NCT# 04370691
- **Abbott LIFE BTK PK**
 Abbott Medical
 Objective: To test the safety and effectiveness of Abbott's Esprit™ BTK scaffold in patients with **critical limb ischemia**. This trial is running in conjunction with a pharmacokinetic sub study.
[Dr. Richard Pin](#)
[Dr. Mark Perry](#)
[Dr. Christopher Tanga](#)
No longer enrolling
 NCT# 04227899 (main study)
 NCT# 05208905 (sub study)
- **Protection Against Emboli During Carotid Artery Stenting Using a Neuroguard IEP Direct 3-in-1 Delivery System Comprised of a Post Dilation Balloon, Integrated Embolic Filter, and a Novel Carotid Stent III/ PERFORMANCE III**
 Contego
 Objective: To evaluate the safety and effectiveness of direct carotid access for stenting using the Neuroguard IEP® Direct System in subjects at elevated risk for adverse events following carotid endarterectomy (CEA) for **carotid artery stenosis**.
[Dr. Richard Pin](#)
[Dr. Mark Perry](#)
Currently enrolling
 NCT# 05845710
- **Prospective, Multi-center, Single Arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the Knee (BTK) Arteries/ DISRUPT PAD BTK**
 Shockwave Medical
 Objective: The objective of this study is to assess the continued safety and effectiveness of the Shockwave Medical Peripheral IVL System for the **treatment of calcified, stenotic BelowTheKnee arteries**.
[Dr. Richard Pin](#)
[Dr. Mark Perry](#)
[Dr. Christopher Tanga](#)
No longer enrolling
 NCT# 05007925
- **Forward-shifted Intravascular Lithotripsy (IVL) Technology in a Prospective, Multi-center, single-arm Investigational Device Exemption (IDE) Study/ FORWARD PAD IDE**



Shockwave Medical

Objective: To assess the safety and effectiveness of the Shockwave Medical JAVELIN Peripheral IVL System for the **treatment of heavily calcified, stenotic peripheral arteries.**

[Dr. Richard Pin](#)

[Dr. Mark Perry](#)

[Dr. Christopher Tanga](#)

No longer enrolling

NCT# 05858905

- **STRIKE PE: A Prospective, Multicenter Study of the Indigo Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism**

Penumbra

Objective: To evaluate real world, long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of **pulmonary embolism.**

[Dr. Richard Pin](#)

[Dr. Mark Perry](#)

[Dr. Christopher Tanga](#)

Currently enrolling

NCT# 04798261

- **ESPRIT BTK Post Approval Study**

Abbott Medical

Objective: Designed to perform a post-market evaluation of the ESPRIT BTK Everolimus Resorbable Scaffold System for the planned treatment of **narrowed infrapopliteal lesions** in real-world settings.

[Dr. Richard Pin](#)

[Dr. Mark Perry](#)

[Dr. Christopher Tanga](#)

Currently enrolling

NCT# 06656364

Persons seeking more information about any of the above trials can search the NCT # on <https://www.clinicaltrials.gov/>.